Treatment for colorectal cancer with signs of remaining disease after therapy
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of two drugs, regorafenib and lorigerlimab, for people with colorectal cancer that has a positive blood test for cancer DNA after they have finished standard treatments. The goal is to see if this treatment can delay or prevent the cancer from coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have had colorectal cancer that was removed by surgery, with or without chemotherapy or other treatments, and you have finished all planned standard treatments.
- A blood test shows there is still cancer DNA in your body, but a CT scan or MRI shows no visible cancer.
- You must be 18 years or older.
- You must be able to do your daily activities with little or no help (performance status 0 or 1).
- Your kidneys, liver, and blood counts must be within a certain range, as determined by blood tests.
- You must not have had certain treatments before, like immune checkpoint inhibitors or other immunotherapies for colorectal cancer.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of a GSL synthesis inhibitor, an immunotherapy drug, and/or regorafenib in people with a specific type of colorectal cancer (pMMR/MSS) that has not responded to at least two prior treatments. The goal is to see if this new approach can help shrink or control the cancer.
This Phase 3 trial tests whether adding a pill called regorafenib to irinotecan “drug-eluting” beads placed in the liver can shrink colorectal cancer that has spread mainly to the liver after standard chemotherapy stops working. If you qualify, it may offer a new combination approach for controlling liver tumors.
This trial tests a combination of two drugs, KN 046 and regorafenib, in people with a type of advanced colorectal cancer that has not responded to previous treatments. The goal is to see if this combination can help shrink or control the tumor.
This trial tests a combination of two drugs, regorafenib and 5-FU with leucovorin, for people with colorectal cancer that has spread and has not responded to at least two previous treatments. The goal is to see if this new mix can help shrink or control the cancer.
This trial tests a combination of regorafenib (a targeted pill that cuts off blood supply to tumors) with a low-dose, continuous chemotherapy regimen for people whose colorectal cancer has spread and is no longer responding to standard treatments. The goal is to see if this mix can slow or stop the cancer's growth.
This trial tests a combination of two drugs (cadonilimab plus regorafenib) as a possible third-line option for people with colorectal cancer that has spread to the liver. It is for patients whose cancer is the MSS/pMMR type and who have already tried standard treatments without success.
Hear when a new Colorectal cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.